167 related articles for article (PubMed ID: 15857146)
41. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
42. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
43. Matrix metalloproteinase inhibitor RO 28-2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer.
Kilian M; Gregor JI; Heukamp I; Hanel M; Ahlgrimm M; Schimke I; Kristiansen G; Ommer A; Walz MK; Jacobi CA; Wenger FA
Prostaglandins Leukot Essent Fatty Acids; 2006 Dec; 75(6):429-34. PubMed ID: 17034997
[TBL] [Abstract][Full Text] [Related]
44. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
Hu J; Van den Steen PE; Sang QX; Opdenakker G
Nat Rev Drug Discov; 2007 Jun; 6(6):480-98. PubMed ID: 17541420
[TBL] [Abstract][Full Text] [Related]
45. Detection of matrix metalloproteinase active forms in complex proteomes: evaluation of affinity versus photoaffinity capture.
Bregant S; Huillet C; Devel L; Dabert-Gay AS; Beau F; Thai R; Czarny B; Yiotakis A; Dive V
J Proteome Res; 2009 May; 8(5):2484-94. PubMed ID: 19271733
[TBL] [Abstract][Full Text] [Related]
46. Repression of matrix metalloproteinase gene expression by ginsenoside Rh2 in human astroglioma cells.
Kim SY; Kim DH; Han SJ; Hyun JW; Kim HS
Biochem Pharmacol; 2007 Dec; 74(11):1642-51. PubMed ID: 17880928
[TBL] [Abstract][Full Text] [Related]
47. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 Sep; 16(17):7932-8. PubMed ID: 18718763
[TBL] [Abstract][Full Text] [Related]
48. New matrix metalloproteinase inhibitors based on γ-fluorinated α-aminocarboxylic and α-aminohydroxamic acids.
Behrends M; Wagner S; Kopka K; Schober O; Schäfers M; Kumbhar S; Waller M; Haufe G
Bioorg Med Chem; 2015 Jul; 23(13):3809-18. PubMed ID: 25921268
[TBL] [Abstract][Full Text] [Related]
49. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
[TBL] [Abstract][Full Text] [Related]
50. Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.
Oltenfreiter R; Staelens L; Hillaert U; Heremans A; Noël A; Frankenne F; Slegers G
Appl Radiat Isot; 2005 Jun; 62(6):903-13. PubMed ID: 15799868
[TBL] [Abstract][Full Text] [Related]
51. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
52. Imaging matrix metalloproteinases in cancer.
Scherer RL; McIntyre JO; Matrisian LM
Cancer Metastasis Rev; 2008 Dec; 27(4):679-90. PubMed ID: 18465089
[TBL] [Abstract][Full Text] [Related]
53. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands.
Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P
J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201
[TBL] [Abstract][Full Text] [Related]
54. Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).
Kim SH; Pudzianowski AT; Leavitt KJ; Barbosa J; McDonnell PA; Metzler WJ; Rankin BM; Liu R; Vaccaro W; Pitts W
Bioorg Med Chem Lett; 2005 Feb; 15(4):1101-6. PubMed ID: 15686921
[TBL] [Abstract][Full Text] [Related]
55. Potent, selective pyrone-based inhibitors of stromelysin-1.
Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
[TBL] [Abstract][Full Text] [Related]
56. Molecular modeling of non-covalent binding of homochiral (3S,3'S)-astaxanthin to matrix metalloproteinase-13 (MMP-13).
Bikádi Z; Hazai E; Zsila F; Lockwood SF
Bioorg Med Chem; 2006 Aug; 14(16):5451-8. PubMed ID: 16716595
[TBL] [Abstract][Full Text] [Related]
57. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.
Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323
[TBL] [Abstract][Full Text] [Related]
58. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT.
Matusiak N; van Waarde A; Bischoff R; Oltenfreiter R; van de Wiele C; Dierckx RA; Elsinga PH
Curr Pharm Des; 2013; 19(25):4647-72. PubMed ID: 23339739
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
[TBL] [Abstract][Full Text] [Related]
60. Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases.
Rasmussen FH; Yeung N; Kiefer L; Murphy G; Lopez-Otin C; Vitek MP; Moss ML
Biochemistry; 2004 Mar; 43(11):2987-95. PubMed ID: 15023050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
